A Phase 2 interventional study of Metformin hydrochloride extended-release tablets and Visually identical placebo Metformin hydrochloride extended-release tablets in Asthma, Asthma Chronic and Overweight and Obesity, sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Asthma by Johns Hopkins University — 3 open to participants now, 4 under way, none of them phase 3. Asthma · Johns Hopkins University.
Among the 33 studies in Asthma by Johns Hopkins University, this one is the 17th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 2, and was the 33rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →3 of the 33 studies in Asthma by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 118 across the 30 interventional studies, 350 across the 3 observational. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
3 of the studies in Asthma by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06273072Johns Hopkins UniversityMetformin IN Asthma for Overweight and Obese Individuals (MINA) | 2026-12-31 |
| NCT05814510Johns Hopkins UniversityImplementation of Asthma Community Home and School Management Program (Asthma CHAMPS) | 2027-06-30 |
| NCT05004714Johns Hopkins UniversityY of Central Maryland Head Start Asthma Implementation | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Asthma by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
This is a randomized, placebo-controlled, parallel-arm pilot clinical trial. Adult participants who are overweight or obese and have not well-controlled asthma despite use of an inhaled corticosteroid will be randomized to metformin, an FDA-approved medication for the treatment of type 2 diabetes mellitus, or to placebo, to be taken daily for a total duration of six months. Recruitment will occur at two sites in the United States.
Randomized participants will have regular telemedicine visits to assess side effects and adherence. Additionally, participants will have a measurement of asthma outcomes at randomization and at 3 and 6 months after randomization.
The purpose of this study is to determine feasibility to inform a future multi-center clinical trial of metformin in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin hydrochloride extended-release tablets 2000 mg once daily
Drug: Metformin hydrochloride extended-release tablets
Placebo tablet once daily
Drug: Visually identical placebo Metformin hydrochloride extended-release tablets
titrated to 2000 mg once daily
placebo
Number of completed telemedicine visits
Number of participants completing at least 3 out of the 4 monitoring telemedicine visits
Time frame: Baseline to week 24
Adherence to study drug
Adherence will be measured by pill count
Time frame: Baseline to week 24
Retention rate
Investigators will collect data on the number of subjects screened, randomized, and complete the final in-person visit
Time frame: Baseline to week 24
Asthma control as assessed by the Asthma Control Test (ACT) score
Difference in Asthma Control Test (ACT) score at week 24; range is from 5-25 with higher being better asthma control
Time frame: Baseline to week 24
Change in Asthma exacerbations rate
Change in (annualized) asthma exacerbations rate at week 24
Time frame: Baseline to week 24
Pre-bronchodilator lung function
Difference in volume of air exhaled in the first second during spirometry (FEV1) at week 24
Time frame: Baseline to week 24
Fractional exhaled nitric oxide (FeNO)
Difference in FeNO between baseline and week 24
Time frame: Baseline to week 24
Airways hyperresponsiveness
Difference in cumulative dose of mannitol required to precipitate a significant decrement in FEV1 between baseline at week 24
Time frame: Baseline to week 24
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 62 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 24 months is below that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin